marked.bio

Company

Haisco Pharmaceutical Group

4 active trials that select patients by a biomarker on marked.bio.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

HSK42360 4cetuximab 1

Trials

4 of 4 trials shown

  1. HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer

    Recruiting Phase 1/2 Haisco Pharmaceutical Group Started 2026Primary completion 2029-09 NCT07790510

    HSK42360cetuximab FDA EUmFOLFOX6oxaliplatinleucovorinfluorouracilFOLFIRIirinotecan

    … (limited to PCR or NGS-based assays) must be provided prior to enrollment to demonstrate BRAF V600 mutation positivity;

    BRAF V600EMetastatic Colorectal Cancer (CRC)

  2. Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation

    Recruiting Phase 1 Haisco Pharmaceutical Group Started 2026Primary completion 2028-12 NCT07561554

    HSK42360

    Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360-Na.

    BRAF V600ESolid Tumors (Phase 1)

  3. Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

    Recruiting Phase 1 Haisco Pharmaceutical Group Started 2025Primary completion 2029-05 NCT07158710

    HSK42360

    Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360.

    BRAF V600EMalignant Brain Tumors

  4. Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

    Recruiting Phase 1 Haisco Pharmaceutical Group Started 2024Primary completion 2026-08 NCT06536400

    HSK42360

    Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360.

    BRAF V600EStatus may be outdated, last updated 2024-08-05Solid Tumors